Payment overview · 2025
General Payments
$417.40
23 reported records · 8 companies
Healthcare provider profile · identity verified
Danny Michael Thornton
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LAKE CITY, FL · NPI 1831774504
Verified facts
What the public records show
CMS Open Payments records show Danny Michael Thornton received $417.40 in general payments during 2025 across 23 reported records.
Novo Nordisk Inc accounted for 34.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $145.73 | 34.9% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.43 | 17.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.35 | 13.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.81 | 10.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.52 | 8.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.82 | 6.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.27 | 5.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.47 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $417.40 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $108.22 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $108.22 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $71.43 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.35 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.81 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.81 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.51 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 23 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 35 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 65 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 70 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
23 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 170 | 51 |
| Lisinopril | Lisinopril | 158 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 156 | 59 |
| Atorvastatin Calcium | Atorvastatin Calcium | 152 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 145 | 48 |
| Methylprednisolone | Methylprednisolone | 135 | 110 |
| Furosemide | Furosemide | 134 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 52 |
| Gabapentin | Gabapentin | 124 | 54 |
| Dexamethasone | Dexamethasone | 115 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 46 |
| Cephalexin | Cephalexin | 99 | 89 |
| Meloxicam | Meloxicam | 96 | 47 |
| Methocarbamol | Methocarbamol | 94 | 51 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 93 | 27 |
| Montelukast Sodium | Montelukast Sodium | 91 | 33 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 90 | 46 |
| Metformin Hcl | Metformin Hcl | 89 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 86 | 40 |
| Omeprazole | Omeprazole | 86 | 30 |
| Trazodone Hcl | Trazodone Hcl | 81 | 30 |
| Losartan Potassium | Losartan Potassium | 79 | 28 |
| Azithromycin | Azithromycin | 78 | 62 |
| Ozempic | Semaglutide | 75 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 34 |
| Potassium Chloride | Potassium Chloride | 74 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 54 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 70 | 60 |
| Rybelsus | Semaglutide | 70 | 16 |
| Ondansetron Odt | Ondansetron | 66 | 37 |
| Mounjaro | Tirzepatide | 65 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 60 |
| Prednisone | Prednisone | 62 | 37 |
| Fluconazole | Fluconazole | 61 | 31 |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 58 | 24 |
| Cefdinir | Cefdinir | 57 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 24 |
| Lorazepam | Lorazepam | 56 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 18 |
| Tramadol Hcl | Tramadol Hcl | 49 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 20 |
| Naproxen | Naproxen | 48 | 41 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 17 |
| Glipizide | Glipizide | 44 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 18 |
| Famotidine | Famotidine | 41 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 41 | suppressed |
| Clonazepam | Clonazepam | 40 | 16 |
| Diazepam | Diazepam | 40 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 22 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | 21 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 18 |
| Jardiance | Empagliflozin | 35 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 35 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 14 |
| Januvia | Sitagliptin Phosphate | 34 | 14 |
| Baclofen | Baclofen | 33 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 11 |
| Ibuprofen | Ibuprofen | 31 | 19 |
| Promethazine Hcl | Promethazine Hcl | 31 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Carvedilol | Carvedilol | 28 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 28 | 22 |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Simvastatin | Simvastatin | 28 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Eliquis | Apixaban | 23 | 11 |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Lactulose | Lactulose | 23 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Colchicine | Colchicine | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $417.40 · 23 records | Novo Nordisk Inc | AREXVY, Cologuard Collection Kit, ELIQUIS, JARDIANCE, Kerendia, MOUNJARO, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Veozah, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error